We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Affordable POC Tests to Improve Early Cancer Detection in Low-Resource Settings

By LabMedica International staff writers
Posted on 31 Oct 2023
Print article
Image: The new research center will develop affordable global health technologies for early cancer detection (Photo courtesy of 123RF)
Image: The new research center will develop affordable global health technologies for early cancer detection (Photo courtesy of 123RF)

Cancer ranks as the first or second leading cause of early death in 134 out of 183 countries. Forecasts suggest that the global rate of cancer cases will surge by 50% between 2018 and 2040. This increase is expected to be more pronounced in countries with fewer resources and inadequate healthcare infrastructure to manage cancer effectively. While early detection and proper treatment can cure most types of cancer, existing diagnostic tests are often too complex or costly to be used in basic healthcare settings, especially in areas with limited medical services. Now, new point-of-care (POC) technologies for early cancer detection aim to bring healthcare services closer to the patient, making treatment timelier and more accessible, which could enhance outcomes in the long run.

Rice University (Houston, TX, USA) is leading a multinational collaboration, involving engineers, cancer specialists, and global health experts from three different continents. The research group has received a grant for up to five years from the National Institutes of Health to set up a leading research facility within the Texas Medical Center. The focus will be on creating cost-effective POC technologies for early cancer detection in both the United States and other nations lacking sufficient healthcare infrastructure. Named the Center for Innovation and Translation of POC Technologies for Equitable Cancer Care (CITEC), the center will operate under the umbrella of the Rice360 Institute for Global Health Technologies. Funded initially by a USD 1.3 million grant from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the center could receive up to USD 6.5 million over the next five years. CITEC will primarily focus on the development of POC diagnostics for oral, cervical, and gastrointestinal cancers.

“CITEC will identify needed technologies, accelerate their development, evaluate their performance and impact in diverse settings and train local users and technology developers to create and disseminate more equitable POC technologies,” said Sharmila Anandasabapathy is vice president of global health at Baylor College of Medicine.

Related Links:
Rice University

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Dengue Virus Test
LINEAR Dengue-CHIK

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Molecular Diagnostics

view channel
Image: Researchers have found the first evidence of testing for the alpha-synuclein protein in blood samples via seed amplification assay (Photo courtesy of Shutterstock)

Blood Test to Detect Alpha-Synuclein Protein Could Revolutionize Parkinson's Disease Diagnostics

Currently, Parkinson's disease (PD) is identified through clinical diagnosis, typically at a later stage in the disease's progression. There is a pressing need for an objective and quantifiable biomarker... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.